Arovella Therapeutics Limited

ASX:ALA Stok Raporu

Piyasa değeri: AU$194.9m

Arovella Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Arovella Therapeutics' CEO is Michael Baker, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is A$558.31K, comprised of 60.9% salary and 39.1% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth A$1.21M. The average tenure of the management team and the board of directors is 1.5 years and 2.7 years respectively.

Anahtar bilgiler

Michael Baker

İcra Kurulu Başkanı

AU$558.3k

Toplam tazminat

CEO maaş yüzdesi60.9%
CEO görev süresi4.8yrs
CEO sahipliği0.6%
Yönetim ortalama görev süresi1.5yrs
Yönetim Kurulu ortalama görev süresi2.7yrs

Son yönetim güncellemeleri

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

CEO Tazminat Analizi

Michael Baker'un ücretlendirmesi Arovella Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024AU$558kAU$340k

-AU$9m

Mar 31 2024n/an/a

-AU$9m

Dec 31 2023n/an/a

-AU$10m

Sep 30 2023n/an/a

-AU$10m

Jun 30 2023AU$528kAU$325k

-AU$10m

Mar 31 2023n/an/a

-AU$9m

Dec 31 2022n/an/a

-AU$9m

Sep 30 2022n/an/a

-AU$9m

Jun 30 2022AU$604kAU$303k

-AU$9m

Mar 31 2022n/an/a

-AU$8m

Dec 31 2021n/an/a

-AU$7m

Sep 30 2021n/an/a

-AU$6m

Jun 30 2021AU$403kAU$275k

-AU$5m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

AU$2m

Sep 30 2020n/an/a

-AU$1m

Jun 30 2020AU$385kAU$124k

-AU$4m

Tazminat ve Piyasa: Michael's total compensation ($USD368.74K) is about average for companies of similar size in the Australian market ($USD299.27K).

Tazminat ve Kazançlar: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Baker

4.8yrs

Görev süresi

AU$558,311

Tazminat

Dr. Michael Baker serves as Chief Executive Officer of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd). since January 2, 2020 and served as its Executive Chairman until July 1, 2...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Michael Baker
CEO, MD & Director4.8yrsAU$558.31k0.62%
A$ 1.2m
Nicole van der Weerden
Chief Operating Officer1.8yrsAU$423.15k0.078%
A$ 152.1k
Timothy Luscombe
Company Secretary & CFOless than a yearVeri yokVeri yok
Michelle Long
Administration Manager1.3yrsVeri yokVeri yok

1.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ALA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Michael Baker
CEO, MD & Director4.8yrsAU$558.31k0.62%
A$ 1.2m
Gary Phillips
Independent Non-Executive Director2.3yrsAU$84.38k0.075%
A$ 145.9k
Elizabeth Stoner
Independent Non-Executive Director3yrsAU$116.13k0.072%
A$ 141.2k
Thomas Duthy
Non-Executive Chair1.7yrsAU$332.53k0.45%
A$ 878.3k
Sattva Neelapu
Member of Clinical Advisory Boardless than a yearVeri yokVeri yok
Gianpietro Dotti
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Debora Barton
Member of Clinical Advisory Board & Independent Non-Executive Director3.3yrsAU$115.94k0.025%
A$ 48.7k
Reuben Benjamin
Member of Scientific Advisory Board3.3yrsVeri yokVeri yok
John Maher
Member of Scientific Advisory Board3.2yrsVeri yokVeri yok
Anastasios Karadimitris
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Salvatore Fiorenza
Chair of Clinical Advisory Boardless than a yearVeri yokVeri yok

2.7yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALA's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.